Tesfay MZ, Cios A, Ferdous KU, Shelton RS, Mustafa B, Simoes CC, Gokden M, Miousse IR, Krager KJ, Boerma M, Urbaniak A, Kunthur A, Obulareddy S, Eichhorn JM, Post SR, Chamcheu JC, Moaven O, Chabu CY, Duda DG, Conti M, Nardo B, Govindarajan R, Fernandez-Zapico ME, Roberts LR, Borad MJ, Cannon MJ, Basnakian AG and Nagalo BM (2025) Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models. Front. Immunol. 16:1679665. doi: 10.3389/fimmu.2025.1679665
Prifti K, Chabu CY, Kobayashi KS, Song J, Han A, de Figueiredo P. Bacterial Therapeutics: Addressing the Affordability Gap in Cancer Therapy. Cancer Res. 2025 Jul 15;85(14):2558-2560. doi: 10.1158/0008-5472.CAN-25-0870. PMID: 40660814.
Tesfay MZ, Zhang Y, Ferdous KU, Taylor MA, Cios A, Shelton RS, Simoes CC, Watters CR, Barro O, Elliott NM, Mustafa B, Chamcheu JC, Graham AL, Washam CL, Alkam D, Gies A, Byrum SD, Giorgakis E, Post SR, Kelly T, Ying J, Moaven O, Chabu CY, Fernandez-Zapico ME, Duda DG, Roberts LR, Govindarajan R, Borad MJ, Cannon MJ, Basnakian AG, Nagalo BM. Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade. Mol Ther Oncol. 2024 Nov 26;32(4):200913. doi: 10.1016/j.omton.2024.200913. PMID: 39758249; PMCID: PMC11697550.
Hartupee C, Nagalo BM, Chabu CY, Tesfay MZ, Coleman-Barnett J, West JT, Moaven O. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Front Immunol. 2024 Feb 1;15:1287459. PMID: 38361931; PMCID: PMC10867137
Rogers CD, Amemiya C, Arur S, Babonis L, Barresi M, Bartlett M, Behringer R, Benham-Pyle B, Bergmann D, Blackman B, Brown CT, Browne B, Camacho J, Chabu CY, Chow I, Cleaver O, Cool J, Dennis MY, Dickinson AJ, Di Talia S, Frank M, Gillmor S, Haag ES, Hariharan I, Harland R, Husbands A, Jerome-Majewska L, Koenig K, Labonne C, Layden M, Lowe C, Mani M, Martik M, McKown K, Moens C, Mosimann C, Onyenedum J, Reed R, Rivera A, Rokhsar D, Royer L, Rutaganira F, Shahan R, Sinha N, Swalla B, Van Norman JM, Wagner DE, Wikramanayake A, Zebell S, Brady SM. Pluripotency of a founding field: rebranding developmental biology. Development. 2024 Feb 1;151(3):dev202342. PMID: 38345109; PMCID: PMC10986740
Vadla GP#, Daghat B#, Patterson N, Ahmad V#, Perez G, Garcia A, Manjunath Y, Kaifi JT, Li G, Chabu CY. Combining plasma extracellular vesicle Let-7b-5p, miR-184 and circulating miR-22-3p levels for NSCLC diagnosis and drug resistance prediction. Scientific Reports. 2022 Apr 23;12(1):6693. PMID: 35461372; PMCID: PMC9035169
Zhou J, Jiang Y, Huang Y, Wang Q, Kaifi JT, Kimchi ET, Chabu CY, Liu Z, Li G. Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy. Translational oncology. 2022 January; 15(1). PubMed PMID: 34768100; PubMed Central PMCID: PMC8591363
Dong YL, Vadla GP#, Lu JJ, Ahmad V#, Klein TJ, Liu LF, Glazer PM, Xu T, Chabu CY. Cooperation between oncogenic Ras and Wild-type p53 stimulates STAT non-cell autonomously to promote tumor radioresistance. Communication Biology. 2021 Mar 19;4(1):374. PubMed PMID: 33742110; PubMed Central PMCID: PMC7979758
Ahmad V, Vadla GP, Chabu CY. Syd/JIP3 controls tissue size by regulating Diap1 protein turnover downstream of Yorkie/YAP. Developmental Biology. 2021 Jan 1; 469:37-45. doi: 10.1016/j.ydbio.2020.09.017. Epub 2020 Oct. PubMed PMID: 33022230
Kazmierczak RA#, Dhagat-Mehta B#, Gulden E, Lee L, Ma L, Davis-Stober CP, Barnett AA, Chabu CY. Evaluations of CRC2631 toxicity, tumor colonization, and genetic stability in the TRAMP prostate cancer model. Oncotarget. 2020 Nov 3;11(44):3943-3958. PubMed PMID: 33216833; PubMed Central PMCID: PMC7646835
Chabu C, Li DM, Xu T. EGFR/ARF6 regulation of Hh signalling stimulates oncogenic Ras tumour overgrowth. Nature Communications. 2017 Mar 10; 8:14688. PubMed PMID: 28281543; PubMed Central PMCID: PMC5353614
Mishra-Gorur K, Çağlayan AO, Schaffer AE, Chabu C, Henegariu O, Vonhoff F, Akgümüş GT, Nishimura S, Han W, Tu S, Baran B, Gümüş H, Dilber C, Zaki MS, Hossni HA, Rivière JB, Kayserili H, Spencer EG, Rosti RÖ, Schroth J, Per H, Çağlar C, Çağlar Ç, Dölen D, Baranoski JF, Kumandaş S, Minja FJ, Erson-Omay EZ, Mane SM, Lifton RP, Xu T, Keshishian H, Dobyns WB, Chi NC, Šestan N, Louvi A, Bilgüvar K, Yasuno K, Gleeson JG, Günel M. Mutations in KATNB1 cause complex cerebral malformations by disrupting asymmetrically dividing neural progenitors. Neuron. 2014 Dec 17;84(6):1226-39. PubMed PMID: 25521378; PubMed Central PMCID: PMC5024344